01 Growing Shift Toward High-Resolution Shotgun Metagenomic Sequencing The cancer microbiome sequencing market is increasingly moving beyond basic 16S rRNA profiling toward shotgun metagenomic sequencing that can characterize microbial communities at species and strain levels while also identifying functional genes and metabolic pathways. High-resolution metagenomics is therefore becoming an important part of cancer microbiome sequencing market trends. In September 2025, PacBio selected 4 projects for its 2025 Microbiome SMRT Grant program from hundreds of proposals. One project specifically applies HiFi shotgun metagenomic sequencing to fecal samples from patients with colorectal adenomas to reconstruct metagenome-assembled genomes and investigate microbial involvement in progression toward colorectal cancer.
02 Increasing Integration of Long-Read Sequencing Into Oncology Workflows Cancer microbiome studies increasingly require sequencing technologies capable of resolving complex microbial genomes, structural variation, and mixed biological signals alongside tumor-related molecular information. Long-read sequencing can provide more complete genomic assemblies and improve identification of microbial organisms that are difficult to characterize using fragmented short reads. Integration with established oncology enrichment and analysis workflows is consequently expanding the cancer microbiome sequencing industry toward more comprehensive translational research. In May 2026, Oxford Nanopore Technologies expanded its compatible sequencing ecosystem across oncology, pathogen, and multi-omics workflows. The program added compatibility with Agilent SureSelect targeted enrichment while extending real-time, any-length sequencing across 3 major areas—oncology, pathogen research, and multi-omics.
01 Growing Evidence Linking the Microbiome With Cancer Development Researchers are identifying microbial communities within tumors and the gastrointestinal tract that may. This is increasing the need to sequence bacteria, fungi, viruses, and other microorganisms alongside host and tumor information. As microbiome signatures become more closely associated with different cancer types, laboratories require increasingly sophisticated sequencing and computational workflows. Expanding evidence around tumor-microbe interactions is therefore strengthening cancer microbiome sequencing market demand.
01 High Host-DNA Content Increases Useful Sequencing Costs Tumor tissue, blood, and other human specimens can contain overwhelmingly more host DNA than microbial DNA. When samples are sequenced without effective host depletion, a large proportion of reads may represent human genetic material rather than microorganisms, requiring substantially deeper sequencing to obtain sufficient microbial information. This increases reagent, sequencing, storage, and bioinformatics costs. Low microbial abundance can consequently restrain cancer microbiome sequencing market growth by making high-quality tumor microbiome studies expensive.
01 Expansion of Microbiome Sequencing for Colorectal Cancer Detection Colorectal cancer offers a significant opportunity because stool samples provide non-invasive access to microbial communities associated with the gastrointestinal tract. Sequencing these communities can potentially identify combinations of microbial species and functional signatures associated with precancerous lesions or cancer. Microbiome-based screening could complement existing stool and colonoscopy approaches while supporting more personalized risk assessment. Non-invasive colorectal screening can therefore help specialized providers increase cancer microbiome sequencing market share.
01 Interpreting Complex Multi-Kingdom Microbial Signals Cancer-associated microbiomes can contain bacteria, fungi, viruses, archaea, and other microorganisms whose abundance may vary substantially between patients, tumor types, anatomical sites, treatments, and populations. Detecting microbial DNA alone does not establish whether an organism contributes to cancer, responds to the tumor environment, or represents contamination. Researchers therefore need large datasets and advanced bioinformatics to distinguish meaningful biological signals from background variation. Reliable interpretation remains a major challenge as cancer microbiome sequencing market size expands toward translational applications.
January 2026 Illumina launched Connected Multiomics, a cloud-based analysis and interpretation platform supporting integrated multiomic workflows. The software enables scalable analysis and visualization of complex biological datasets, including applications in oncology and microbiome-linked research.
January 2026 QIAGEN advanced three automated sample-preparation systems for 2026 launches, targeting high-throughput applications including microbiome research, liquid biopsy, and oncology workflows.
May 2025 MapmyGenome acquired Microbiome Insights, a Canadian microbial sequencing specialist with a CAP-accredited laboratory and microbiome-focused intellectual property. The acquisition expanded MapmyGenome's microbial sequencing and microbiome analysis capabilities and strengthened its international genomics operations.